Skip to main content
main-content

Oncology

Latest articles

27-03-2017 | Breast cancer | News | Article

Brain metastases in newly diagnosed breast cancer patients profiled

Patients with hormone receptor-negative/human epidermal growth factor receptor 2-positive breast cancer have the highest incidence of brain metastases at diagnosis, followed by those with triple-negative disease, population-based study data show.

Source:

JAMA Oncol 2017; Advance online publication

27-03-2017 | Lymphoma | News | Article

News in brief

Rare breast implant-related lymphoma highlighted

The US Food and Drug Administration has issued an updated safety alert regarding breast implant-associated anaplastic large cell lymphoma.

24-03-2017 | Oncology | News | Article

Intestinal microbiota linked to reduced risk for post-HSCT relapse

Researchers have found an association between increased abundance of a bacterial group primarily comprising Eubacterium limosum in the intestinal microbiota and a reduced risk for relapse after undergoing allogeneic hematopoietic stem cell transplantation.

Source:

J Clin Oncol 2017; Advance online publication

24-03-2017 | Breast cancer | News | Article

News in brief

Triple-positive breast cancer patients with diabetes benefit from metformin

Researchers recommend the use of the antidiabetic agent metformin for the subset of women with human epidermal growth factor receptor-positive and hormone receptor-positive breast cancer who also have diabetes.

23-03-2017 | Lymphoma | News | Article

Excessive toxicity halts idelalisib, lenalidomide plus rituximab lymphoma trials

Two phase 1 trials investigating the safety and efficacy of combined idelalisib, lenalidomide, and rituximab in patients with relapsed and refractory follicular and mantle cell lymphoma have been stopped early due to excessive toxicity.

Source:

Lancet Haematol 2017; Advance online publication

22-03-2017 | Prostate cancer | News | Article

News in brief

No increase in prostate cancer risk with testosterone replacement

Testosterone replacement therapy is not associated with an increase in total prostate cancer risk, and may even decrease the risk for aggressive disease.

image credits